Evotec's Q1 Miss Sets the Stage for a Strategic Pivot

Evotec's first-quarter 2026 results landed exactly as management had flagged—weak on paper, but full of forward-looking signals. Group revenues fell 21.7% to EUR 156.6 million and adjusted EBITDA swung to negative EUR 21.9 million, driven by the nonrecurrence of a EUR 23.1 million Sandoz license payment, FX headwinds of EUR 10.2 million, and continued softness in early-stage drug discovery demand. “In the first quarter of 2026, we advanced Evotec's value creation levers, most notably with the initiation of the Horizon business transformation” — Christian Wojczewski, CEO · 2026-05-06, CEO Christian Wojczewski noted. The full-year guidance was reaffirmed, implying a sharp ramp in the back half. CFO Claire Hinshelwood explained the dynamics: “Group revenues for the first quarter of 2026 amounted to EUR 156.6 million, representing a decrease of EUR 43.4 million or 21.7% compared to the same period in 2025” — Claire Hinshelwood, Chief Financial Officer · 2026-05-06, but pointed to strategic partnerships and an improving D&PD environment as the key second-half drivers.

Horizon and the Strategic Review: A New Operating Model

The Horizon initiative is now moving from announcement to implementation. The company booked EUR 75 million in restructuring provisions during Q1, covering severance and impairment costs, and expects EUR 75 million in structural run-rate savings by 2027, with 20–30% realized in 2026. Site exits in Europe are progressing through works council consultations, and the first personnel adjustments are slated for Q3. More striking is the simultaneous launch of a strategic review.

With this optimized foundation in place, it's the right time to conduct a strategic evaluation to assess how the value being created through this transformation is most effectively realized within the corporate structure of the company.

Fragile Signs of Stabilization in D&PD

Underneath the headline weakness, a few leading indicators are turning. Negative change orders declined further in Q1, reaching their lowest level since early 2025. Proposal activity in discovery and preclinical development hit a 12-month high, and net sales orders were flat versus Q4 but up 15% year-over-year. The company's order book is expected to rebuild in H2, a point CEO Wojczewski emphasized: "We're now starting to rebuild the order book, and there will be an inflection point in the second half where the order book is also starting to grow." Yet the market remains soft, and management was careful not to call a full recovery. In prior quarters, they had noted “We've actually provided you today with a little bit of data and statistics to underpin maybe what has been a bit more anecdotal in the last couple of calls” — Christian Wojczewski, CEO · 2025-08-13, indicating that this time the improvement is more concrete.

Leadership, AI, and the Road Ahead

The quarter also brought fresh leadership: Claire Hinshelwood stepped in as CFO and Ingrid Muller as COO, both with deep operational and transformation experience. Their appointments are meant to bolster the execution of Horizon and align the commercial organization with the company's new priorities. Meanwhile, AI remains a growth lever. In past earnings calls, the company highlighted its AI and alternative-to-animal-testing capabilities—“Evotec is really uniquely positioned to serve this developing market” — Cord Dohrmann, Head of Pipeline/Research or similar · 2025-04-17—and this quarter reiterated that AI-driven demand is emerging from both pharma and AI-native companies. While the near-term picture is clouded by the license payment hangover and FX, the combination of a formal strategic review, a visibly progressing cost program, and leading indicators that are finally pointing upward makes this a name to watch. The next few quarters will determine whether Evotec's transformation is just restructuring or a true re-rating of the business.